Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
First launches expected in H1 2022
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The centralized marketing authorization granted by the EC is valid in all EU Member
Subscribe To Our Newsletter & Stay Updated
